Search research articles
Contact Us
Filters
Showing results (21-30 of 45) with videos related to
Page
of 5
Sort By:
American Journal of Clinical Pathology
|
June 1, 1984
Serum testosterone measurements
W J Boyle, A A Compton, G Rigg, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research
|
January 26, 2000
The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption
L C Hofbauer, S Khosla, C R Dunstan, et al.
Cell
|
February 8, 1991
Activation of protein kinase C decreases phosphorylation of c-Jun at sites that negatively regulate its DNA-binding activity
W J Boyle, T Smeal, L H Defize, et al.
Nature
|
March 10, 1988
Oncogene jun encodes a sequence-specific trans-activator similar to AP-1
P Angel, E A Allegretto, S T Okino, et al.
Journal of Virology
|
March 1, 1988
Subnuclear localization of the trans-activating protein of human T-cell leukemia virus type I
D J Slamon, W J Boyle, D E Keith, et al.
Journal of Cellular Biochemistry
|
February 18, 1999
Osteoprotegerin and osteoprotegerin ligand effects on osteoclast formation from human peripheral blood mononuclear cell precursors
V Shalhoub, J Faust, W J Boyle, et al.
Cold Spring Harbor Symposia on Quantitative Biology
|
January 1, 1988
Targets for signal-transducing protein kinases
T Hunter, P Angel, W J Boyle, et al.
The Journal of Cell Biology
|
May 4, 1999
The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts
T L Burgess, Y Qian, S Kaufman, et al.
The Journal of Experimental Medicine
|
August 22, 2000
Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis
H Min, S Morony, I Sarosi, et al.
Genes & Development
|
June 6, 1998
osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification
N Bucay, I Sarosi, C R Dunstan, et al.
Page
of 5
Search research articles
Search
Showing results (21-30 of 45) with videos related to
Sort By:
Page
of 5
American Journal of Clinical Pathology
|
June 1, 1984
Serum testosterone measurements
W J Boyle, A A Compton, G Rigg, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research
|
January 26, 2000
The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption
L C Hofbauer, S Khosla, C R Dunstan, et al.
Cell
|
February 8, 1991
Activation of protein kinase C decreases phosphorylation of c-Jun at sites that negatively regulate its DNA-binding activity
W J Boyle, T Smeal, L H Defize, et al.
Nature
|
March 10, 1988
Oncogene jun encodes a sequence-specific trans-activator similar to AP-1
P Angel, E A Allegretto, S T Okino, et al.
Journal of Virology
|
March 1, 1988
Subnuclear localization of the trans-activating protein of human T-cell leukemia virus type I
D J Slamon, W J Boyle, D E Keith, et al.
Journal of Cellular Biochemistry
|
February 18, 1999
Osteoprotegerin and osteoprotegerin ligand effects on osteoclast formation from human peripheral blood mononuclear cell precursors
V Shalhoub, J Faust, W J Boyle, et al.
Cold Spring Harbor Symposia on Quantitative Biology
|
January 1, 1988
Targets for signal-transducing protein kinases
T Hunter, P Angel, W J Boyle, et al.
The Journal of Cell Biology
|
May 4, 1999
The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts
T L Burgess, Y Qian, S Kaufman, et al.
The Journal of Experimental Medicine
|
August 22, 2000
Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis
H Min, S Morony, I Sarosi, et al.
Genes & Development
|
June 6, 1998
osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification
N Bucay, I Sarosi, C R Dunstan, et al.
Page
of 5